Related Experiment Videos
Beta-blockers and spironolactone in heart failure
1Director, Heart Failure Program, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, New York, NY 10029, USA.
Current Cardiology Reports
|September 12, 2000
Abstract:
Neurohormonal antagonism is now recognized as an essential treatment modality for heart failure. As a prime example, the benefits of blocking the renin-angiotensin system with angiotensin converting enzyme inhibitors are clearly established for all four New York Heart Association classes. In this clinical trials review, we discuss two other therapies with neurohormonal targets: beta-blockers and the sympathetic nervous system, and the aldosterone antagonist spironolactone.